TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11245027
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (CP, CAP, or CEP, E = VP16)
Study: 3277481
Drug: Oral atropine
Normalized name: atropine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atropine 0.04 mg/kg
Study: 3277481
Drug: Oral atropine
Normalized name: atropine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atropine 0.02 mg/kg
Study: 2310661
Drug: Intravenous hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydralazine
Study: 28521880
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose
Study: 26041653
Drug: Brief behavioural
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief behavioural intervention to promote regular self-weighing, including daily weighing encouragement and support materials such as a weight record card
Study: 11312429
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied twice daily for 6 weeks
Study: 11312429
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied once daily for 6 weeks
Study: 11312429
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied twice daily 3 times/week for 6 weeks
Study: 11312429
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied once daily 3 times/week for 6 weeks
Study: 7956718
Drug: Theophylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5 mg/kg) in oral solution
Study: 25173483
Drug: M-001 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-001 (500 mcg, non-adjuvanted or adjuvanted)
Study: 22850914
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (IT) with weekly visits for medication adjustments and educational plan for six weeks
Study: 19435491
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (IT)
Study: 18408560
Drug: Albuterol (short-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (short-acting beta2-agonist)
Study: 15759530
Drug: Bobath treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bobath treatment
Study: 1791612
Drug: nisoldipine 5
Normalized name: nisoldipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nisoldipine 5 mg twice daily
Study: 1791612
Drug: nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 10 mg twice daily
Study: 2684134
Drug: Standard behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioural treatment
Study: 31452920
Drug: ENHANCED (technology-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENHANCED (technology-supported treatment with digital scale and Fitbit Zip)
Study: 31452920
Drug: Standard behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioural treatment and ENHANCED
Study: 22490950
Drug: 0.5% Loteprednol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Loteprednol Etabonate ophthalmic suspension
Study: 12021221
Drug: tirofiban/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirofiban/heparin
Study: 8094768
Drug: heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin alone
Study: 10208508
Drug: Model topical
Normalized name: Model AA 2012 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model topical agent
Study: 1972611
Drug: Acebutolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (0.1 mg/kg i.v. bolus over 30 s)
Study: 1972611
Drug: Esmolol (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (loading dose 500 micrograms/kg over 1 min followed by 100 micrograms/kg per min continuous infusion)
Study: 418585
Drug: Oral thyrotropin
Normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thyrotropin releasing hormone (TRH) 40 mg
Study: 31765428
Drug: Four-component combination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-component combination pill (polypill)
Study: 27640727
Drug: Hypodermoclysis administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypodermoclysis administered by caregivers after a 45-minute training session
Study: 24794289
Drug: Serious games
Normalized name: Encora AM Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serious games (SG) as an adjuvant to conventional treatment
Study: 24794289
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for CP
Study: 24843499
Drug: Liraglutide 0.6
Normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.6 mg/day
Study: 18025845
Drug: Periprostatic bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic bupivacaine (0.5% 20 ml) injection (group I)
Study: 18025845
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline NaCl 0.9% 20 ml injection, group II)
Study: 1535653
Drug: Korean HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean HBV vaccine
Study: 1535653
Drug: U.S. HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: U.S. HBV vaccine
Study: 6532586
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a specific vasopressin antagonist acting at the vascular site
Study: 9578335
Drug: Psyllium (7.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium (7.4 g)
Study: 7523130
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal treatment with GnRH analogue (triptorelin) for 3 months
Study: 2694858
Drug: Alfentanil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil combination anaesthesia
Study: 2694858
Drug: Ethrane inhalation
Normalized name: Ethrane Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethrane inhalation anaesthesia
Study: 902677
Drug: Indomethacin alone
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin alone (preparation C)
Study: 902677
Drug: Indomethacin-antacid combination
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin-antacid combination (preparation A)
Study: 902677
Drug: Indomethacin-antacid combination
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin-antacid combination (preparation B)
Study: 25086659
Drug: RIS+OLZ (augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIS+OLZ (augmentation with olanzapine)
Study: 25086659
Drug: OLZ-RIS (augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ-RIS (augmentation with risperidone)
Study: 19640677
Drug: Individual cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behavioral family-based therapy (CBFT)
Study: 19640677
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral family-based therapy (CBFT)
Study: 14615876
Drug: Psilocybin (PY)
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (PY) - 45 microg/kg (very low dose)
Study: 14615876
Drug: Psilocybin (PY)
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (PY) - 115 microg/kg (low dose)
Study: 14615876
Drug: Psilocybin (PY)
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (PY) - 215 microg/kg (medium dose)
Study: 14615876
Drug: Psilocybin (PY)
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (PY) - 315 microg/kg (high dose)
Study: 3056751
Drug: Adjuvant hormono-chemotherapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormono-chemotherapy (Tamoxifen for 6 months, and 6-monthly cycles of vincristine, adriamycin, and cyclophosphamide)
Study: 519956
Drug: Propranolol (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (single oral dose)
Study: 28136072
Drug: Pazopanib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (800 mg once daily for up to 24 months)
Study: 21932561
Drug: Stepwise increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise increase in the extent of combined salmoterol/fluticason therapy
Study: 21932561
Drug: Long-term stable-dose
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term stable-dose salmoterol/fluticason therapy
Study: 21932561
Drug: Salmoterol/fluticason therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmoterol/fluticason therapy with gradual decrease of the dose and/or transition to an alternative variant
Study: 19825213
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk containing Lactobacillus acidophilus 145 and Bifidobacterium longum BB536 (125 g three times a day for 4 weeks)
Study: 15193791
Drug: Dentine bonding
Normalized name: dendropanax dentiger root with stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentine bonding agent (DBA) - Prime & Bond NT applied after acid-etching
Study: 2003792
Drug: Topical 0.01%
Normalized name: tretinoin topical 0.01% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.01% dexamethasone sodium phosphate drops
Study: 22950711
Drug: Nimodipine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (90 mg/d)
Study: 8487598
Drug: Nicardipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (60 mg/d)
Study: 4037255
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride 1 mg/ml
Study: 4037255
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride 5 mg/ml
Study: 4037255
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride 10 mg/ml
Study: 26839144
Drug: Abituzumab 750
Normalized name: sacituzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abituzumab 750 mg
Study: 26839144
Drug: Abituzumab 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abituzumab 1,500 mg
Study: 25280410
Drug: Fructose supplementation
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose supplementation (120 g/d for 3 days)
Study: 16295154
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus 3 hours contact with a pediatric nurse practitioner (PNP) for counseling, instruction, and assistance with implementation of the recommended treatment plan
Study: 16295154
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (1-hour consultation session and written treatment plan)
Study: 28395131
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (220 mg zinc sulfate containing 50 mg elemental zinc daily for 12 weeks)
Study: 23686379
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care + daily CP mouth rinses (n=27)
Study: 22139337
Drug: Betacarotene (BC)
Normalized name: betacarotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betacarotene (BC) group supplemented daily with 50 mg of BC (n=9; LW: 17.3±1.0 kg; BCS: 3.34±0.12)
Study: 19109408
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg in pellet form
Study: 17003088
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (sc insulin)
Study: 11261319
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g once daily plus tobramycin 5 mg/kg
Study: 11261319
Drug: Cefotaxime 2
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 2 g three times daily plus tobramycin 5 mg/kg
Study: 9249099
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg intravenous ibuprofen
Study: 8034237
Drug: 5,000 IU
Normalized name: bleopmycin 15,000 IU Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5,000 IU unfractionated (UF) heparin
Study: 8034237
Drug: 1,500 activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 activated partial thromboplastin time units low molecular mass (LMM) heparin
Study: 2894979
Drug: Felodipine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5, 10, 20 mg bid)
Study: 2894979
Drug: Prazosin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (1, 2, 4 mg bid)
Study: 17371337
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg/day)
Study: 26512149
Drug: Garcin tablets
Normalized name: GARCINIA MANGOSTANA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garcin tablets 1,500 mg daily for 7 days
Study: 26512149
Drug: Fluconazole tablets
Normalized name: Fluconazole Tablets
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole tablets 150 mg daily for 7 days
Study: 23221480
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with tamsulosin (0.4 mg) and fesoterodine extended-release
Study: 23221480
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of tamsulosin (0.4 mg)
Study: 21975559
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5 mg IV infusion)
Study: 16868359
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg dried garlic powder
Study: 10487669
Drug: Hydrocortisone administration
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administration at 1700 h
Study: 10487669
Drug: Hydrocortisone administration
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administration at 0500 h
Study: 3493794
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 mg kg‐1
Study: 6811237
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g human immunoglobulin i.v. over four months
Study: 21310051
Drug: ondansetron syrup
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron syrup (0.15 mg/Kg of body weight)
Study: 21310051
Drug: domperidone syrup
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: domperidone syrup (0.5 mg/Kg of body weight)
Study: 19797255
Drug: Spontaneous or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spontaneous or inducible VT as indication for ICD therapy
Study: 9462489
Drug: 11 mg/d
Normalized name: ProStep 11 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 mg/d transdermal nicotine
Study: 9462489
Drug: 22 mg/d
Normalized name: ProStep 22 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg/d transdermal nicotine
Study: 9462489
Drug: 44 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 mg/d transdermal nicotine
Study: 1970466
Drug: Zidovudine, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 200 mg orally every 4 hours
Study: 6861859
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of furosemide
Study: 27903345
Drug: 70 kV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 kV CT angiography with 0.8 ml/kg contrast agent
Study: 27903345
Drug: 120 kV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 kV CT angiography with 100 ml contrast agent
Study: 25445073
Drug: Exposure-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based therapy with safety behavior assessment
Study: 22178539
Drug: Neridronate 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate 12.5 mg
Study: 11892710
Drug: Neridronate 25
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neridronate 25 mg
Study: 11892710
Drug: Neridronate 50
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neridronate 50 mg
Study: 21130385
Drug: Omalizumab (minimum,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (minimum, 0.016 mg/kg/IU (IgE/mL) every 4 weeks)
Study: 11096224
Drug: Rivastigmine (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (6-12 mg/day)
Study: 12413703
Drug: Phytodrug (QG-5)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytodrug (QG-5) from guava leaves, 500 mg capsules administered every 8 hours for 3 days
Study: 2109467
Drug: Midazolam with
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam with low doses of phenoperidine for sedation and amnesia during cataract surgery
Study: 7247000
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg piritramide
Study: 7247000
Drug: 0.003 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.003 mg/kg fentanyl
Study: 29131352
Drug: Intravenous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ethanol infusion at 100 mg%
Study: 29131352
Drug: Intravenous ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ethanol infusion at higher doses
Study: 26291199
Drug: Selexipag (compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (compound 26a)
Study: 24831989
Drug: Intensified insulin-based
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin-based glycaemic control for at least 3 months
Study: 24831989
Drug: Conventional glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose-lowering treatment (Control)
Study: 17324253
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine acupuncture-care and self-care (10 sessions over 12 weeks)
Study: 17324253
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine acupuncture-care and self-care
Study: 11445753
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment group, met three times/week throughout the study
Study: 8280654
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 160 mg daily
Study: 25919112
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (1000 μg daily) for 4 weeks
Study: 25919112
Drug: rs7772821 (T>G)
Normalized name: (T,G)-A-L
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs7772821 (T>G) polymorphism
Study: 22194988
Drug: Low-dose flutamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose flutamide, metformin, and pioglitazone in combination with an estro-progestagen
Study: 11169056
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2a 6 million units three times weekly plus ribavirin 14 mg/kg per day (n=93)
Study: 8250106
Drug: Quinine (17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (17 mg/kg over 4.5 hr)
Study: 8250106
Drug: Prochlorperazine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (12.5 mg intramuscularly)
Study: 30230694
Drug: Oral cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cabotegravir 30 mg after a high-fat meal (∼53% fat, ∼870 kcal)
Study: 30230694
Drug: Oral cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cabotegravir 30 mg after fasting
Study: 19250003
Drug: Intravenous micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous micronutrient therapy (IVMT)
Study: 17827929
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 mg daily for 48 weeks)
Study: 17827929
Drug: Alfacalcidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (0.5 microg daily for 48 weeks)
Study: 3278581
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg twice daily)
Study: 7946944
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg twice daily)
Study: 26019023
Drug: Low-fat spread
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat spread enriched with plant sterols (PS) and eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at doses of 0.0, 0.9, 1.3, and 1.8 g/day for 4 weeks
Study: 21452357
Drug: Active PEMF
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PEMF treatment (pulsing electromagnetic field) worn on the distal forearm for 1, 2, or 4 hours/day for 8 weeks.